Deep Dive

A Life in a Day by The Method

Patient centricity has become a key aspiration for the pharma industry over the last several years, but getting entire organisations to think and behave in a patient-centric way can be challenging. The Method is an innovative learning and development company delivering a ground-breaking programme designed to achieve tangible patient-centric results within pharma and healthcare The …

A Life in a Day by The Method Read More »

Translating EU presence to US market success

Companies looking to replicate a drug’s EU market success in the US will face significant hurdles unless they are fully aware of the ever-changing national and state requirements and regulations, says Two Labs’ Howard Miller. As the world’s largest single pharmaceutical market, the US should – at least at first glance – provide a simplified …

Translating EU presence to US market success Read More »

Navigating the patient maze – pharma’s evolving challenge

Pharma companies are embracing patient centricity in drug development more than ever before. Over the last decade, leaders in the industry have championed patient engagement, putting it at the heart of commercial strategies. It’s a hard task to get right though, as ICON’s Chris O’Toole explains, but the rewards can be huge on both sides. …

Navigating the patient maze – pharma’s evolving challenge Read More »

It’s time to rethink the physician-pharma relationship

The traditional sales channel for the pharmaceutical industry has centered on face-to-face interaction with its core target audience – prescribing physicians. What happens when suddenly that form of interaction is taken away? Michael Brandreth, group vice president at WebMD Global, tells us how the events of the last 18 months make it more important than …

It’s time to rethink the physician-pharma relationship Read More »

Refining digital collaboration

Pharmaceutical companies are traditionally more conservative with their approach to and incorporation of new technologies; however, prior to COVID, the industry had begun moving toward intersecting health and technology. Natalie Yeadon, Co-founder and CEO of Impetus Digital, tells us how COVID has accelerated digital health transformation and made effective virtual collaboration more important than ever. …

Refining digital collaboration Read More »

Closing pharma’s communication gap with patients

The pharma industry has been talking about being patient-centric for years, but often that rhetoric hasn’t been accompanied by real change in the way product development is carried out. Keri McDonough thinks there is still a still a void between some pharma and patients, but one that can be bridged by developers who make a …

Closing pharma’s communication gap with patients Read More »

Leveraging a strong product launch to build a successful pharma brand

So much effort goes into ensuring the successful launch of a new pharmaceutical product or indication, but it’s only once that has been achieved that the real work begins, says Align Strategy’s Christine Fletcher. Introducing a new pharmaceutical brand is akin to asking someone to change their established habits, and first impressions of that treatment …

Leveraging a strong product launch to build a successful pharma brand Read More »

The post-pandemic evolution of pharma-doctor digital interactions

M3’s Tim Russell and Maxim Polyakov, together with Digital Futureway’s Heather Hancock, discuss new research on how doctor engagement has been altered by COVID-19. COVID-19 forced an unprecedented shift towards the virtual delivery of healthcare, suddenly compelling doctors increasingly to use digital means to care for their patients. As healthcare resources and delivery were prioritised, …

The post-pandemic evolution of pharma-doctor digital interactions Read More »

Deep Dive: Communications and Commercialisation

The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. In some cases it was an accelerant for existing plans, but it has also caused some new shifts in the landscape, shifts that have yet to be completed. This issue assesses European pharma’s approach to strategic …

Deep Dive: Communications and Commercialisation Read More »

Cancer research faces uncertain post-COVID landscape

There’s a bright future ahead for cancer research in the UK, but only if the government is able to implement a clear plan for funding and development going forward, says The Institute of Cancer Research, London’s Paul Workman. Cancer research in the UK risks facing a “perfect storm” of stalled work and reduced funding that …

Cancer research faces uncertain post-COVID landscape Read More »

Surprise pandemic lessons for pharma

Ask people in most western nations to think back to 2019 and consider what they would have said then about the potential impact of a pandemic on their everyday lives and my guess is that the vast majority of us would have had little insight into what would happen. Residents of Southeast Asia who had …

Surprise pandemic lessons for pharma Read More »

Lessons from the first generation of cell and gene oncology trials

Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for these therapies. ICON’s Tamie Joeckel and Brandon Fletcher take us through best-practice approaches to CGT studies and discuss what the future could hold for this exciting area. Cell and gene …

Lessons from the first generation of cell and gene oncology trials Read More »

Oncology R&D: the patient insights we’re still missing, and how to catch up

Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and overcrowded. You are under pressure to bring solutions now, and for your entire career, you have been taught that things must be done a certain way. Patient engagement is viewed by many as a nice-to-have rather than …

Oncology R&D: the patient insights we’re still missing, and how to catch up Read More »

Digital tools key to immuno-oncology’s future: report

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the field becomes more crowded, digital tools may be critical for improving outcomes, says a new whitepaper. The whitepaper, ‘The Role of Digital Health in Immuno-oncology Therapy Development and Adoption’ from …

Digital tools key to immuno-oncology’s future: report Read More »

Oncology and a year of COVID: lessons for the future

COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting change in research, practice and education, says Lucid’s Frances O’Connor. The COVID-19 pandemic might finally be in its latter stages after a year and a half of disruption, but its …

Oncology and a year of COVID: lessons for the future Read More »

How hybrid virtual engagement is accelerating oncology communication

COVID has revolutionised the way pharma engages with healthcare stakeholders – but to be truly successful, digital engagement needs to move away from an overreliance on real-time meetings, say experts from Within3. By making virtual meetings a necessity, COVID has forced pharma to adopt a more flexible, digitally-driven approach to stakeholder interaction – but in …

How hybrid virtual engagement is accelerating oncology communication Read More »

Enabling healthcare’s digital future

Debiopharm Innovation Fund’s Tanja Dowe on investing in digital health start-ups and supporting them on their rollercoaster rides to improve patient outcomes The weight of expectation hangs heavy over the digital health sector. Even before COVID-19 struck, shattering established societal and healthcare norms, much was expected from start-ups that could combine health and tech. Now, …

Enabling healthcare’s digital future Read More »

Digital health developments: a new investment era for start-ups

Healthware Labs’ Kristin Milburn explores how digital health start-ups can harness the huge potential for the sector in a post-COVID world and the paths they need to take to grow their business. Digital health has come a long way in the past decade – and Kristin Milburn says that the sector could now be about …

Digital health developments: a new investment era for start-ups Read More »

Why pharma shouldn’t forget about sites in a post-COVID world

The pandemic forced massive changes to oncology sites to ensure patient safety and research continuity – but we must recalibrate and work with sites to understand the value proposition of the technologies and methodologies adopted, says Syneos Health’s Angela Hirst. Formerly an oncology nurse and now director of Sites and Patient Services at Syneos Health’s …

Why pharma shouldn’t forget about sites in a post-COVID world Read More »

How digital pathways are changing healthcare

As demonstrated throughout COVID, digital health is no longer experimental. Digital technologies are proving their value by allowing for better care, improved adherence and a more connected ecosystem between doctors, patients and pharma. Ampersand Health has been working in the space since 2015 and has seen it evolve from a niche approach with limited acceptance …

How digital pathways are changing healthcare Read More »

Turning words into actions with patient engagement

Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together to design actionable projects for pharma-patient engagement. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: As pharma seeks new and better …

Turning words into actions with patient engagement Read More »

Turning words into actions with patient engagement

Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together to design actionable projects for pharma-patient engagement. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: As pharma seeks new and better …

Turning words into actions with patient engagement Read More »

How the patient voice is becoming vital for drug approval

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read below for …

How the patient voice is becoming vital for drug approval Read More »

“A long way to go” for digital health reimbursement

A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a smoother path to market. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: In many ways, the healthcare sector is still wrestling …

“A long way to go” for digital health reimbursement Read More »

Time for a NICE change

The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of how the world has changed over its history, NICE is coming to the end of a period of review and consultation on their processes and methods. Leela Barham takes stock. …

Time for a NICE change Read More »

Rethinking access barriers to innovation

Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages. This article appears in our digital magazine Deep Dive: Market Access 2021. Read on …

Rethinking access barriers to innovation Read More »

AI meets RWE: The future of drug assessment?

Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for pharma and regulators. This article appears in out digital magazine Deep Dive: Market Access 2021. Read below for a preview: Real world evidence (RWE) is rapidly evolving. Having gone from being …

AI meets RWE: The future of drug assessment? Read More »

Listening to ultra-rare disease communities

When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global commercial biopharmaceutical company pioneering therapies for ultra-rare diseases, PTC Therapeutics is familiar with the challenges. The company prides itself on a patient-centric approach to treatment but there can be significant hurdles in patients accessing potentially life-changing treatments. …

Listening to ultra-rare disease communities Read More »

How to improve payer engagement with tailored value communication

Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate strong value propositions in increasingly crowded therapeutic areas. However, value can mean different things to different payers. In this article, Cecilie Alstad, senior analyst at Research Partnership, discusses how an approach established in the world of marketing …

How to improve payer engagement with tailored value communication Read More »

From representation to empowerment: Putting patients at the centre of medicine reimbursement

Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this. This article appears in full in our digital magazine Deep Dive: Market Access 2021. Read below for a sneak-peak: The reimbursement landscape in Europe is complex. There …

From representation to empowerment: Putting patients at the centre of medicine reimbursement Read More »

How will NICE fare in a post-Brexit world?

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage. This article appears in our digital magazine, Deep Dive: Market Access …

How will NICE fare in a post-Brexit world? Read More »

Research predicts the post-COVID landscape for HCP engagement

IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes. This article appears in full in Deep Dive: Market Access 2021. Read a preview below: Recent ChannelDynamics data from IQVIA shows that while there has been a marked …

Research predicts the post-COVID landscape for HCP engagement Read More »

A year on: pandemic driven trends in HCP engagement

IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. This article appears in full in this month’s Deep Dive digital magazine on Market Access. Here is a preview: As we reach the end of the first quarter of 2021, our customers continue …

A year on: pandemic driven trends in HCP engagement Read More »

Deep Dive: Market Access

It’s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to work towards approving drugs and vaccines in record times, the sector is also facing an influx of digital therapeutics and advanced drugs that don’t fit neatly into existing access frameworks. …

Deep Dive: Market Access Read More »

Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company

From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become one of the top manufacturers of cell culture media. Although Irvine Scientific joined parent company Fujifilm in 2018, its roots can be traced back to the 1970s, where it started …

Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company Read More »

LEO Pharma’s new R&D lead on driving agility in drug development

After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development. We spoke to him about the lessons he’s taking from his prior jobs into the new role and what it means to be an R&D leader in the modern industry. As global head of research …

LEO Pharma’s new R&D lead on driving agility in drug development Read More »

Inside the UK’s leading efforts to restart clinical research

A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute for Health Research’s (NIHR) Restart Framework. Experts from the institute tell us how those numbers can be further boosted, and how lessons learned from the sector-wide collaboration will change UK research forever. There has been a remarkable …

Inside the UK’s leading efforts to restart clinical research Read More »

Focus on Rare: the invisible burden of rare diseases

Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. Over the past decade there has been considerable investment by pharma into research for rare disease as the patient voice and advocacy movement have done an outstanding job of raising …

Focus on Rare: the invisible burden of rare diseases Read More »

The post-COVID face of pharma research and development

The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response to some long-standing issues with the clinical trials process.  Lockdown rules and safety protocols certainly made it harder for patients to travel to trial sites, while a refocusing …

The post-COVID face of pharma research and development Read More »

Patient partnerships: putting relevance into relationships

There are perhaps two ways to look at 2020 – on the surface, it has been a year of pandemic health catastrophe, on a deeper level it has been a year where we finally acknowledged the fragility of health partnerships and the importance of good relationships between the pharmaceutical industry and the patients it serves. …

Patient partnerships: putting relevance into relationships Read More »

3 practical steps for improving patient support

Research Partnership’s Emilie Braund and Harrison Gaiger dig down into the top insights pharma companies can harness to make their patient support programmes as powerful as possible. The pandemic has undoubtedly disrupted the healthcare landscape and amplified the complex factors that influence and shape patient journeys. Findings from our recently published whitepaper ‘Free thinking: The …

3 practical steps for improving patient support Read More »

A collaborative approach to greater diversity in clinical trials

The need for diversity in clinical trial populations has been a topic of discussion across regulators and the industry in general for decades. Despite the introduction of US policies, beginning with the 1993 National Institutes of Health (NIH) Revitalization Act which called for the inclusion of more women and communities of colour in clinical trials, …

A collaborative approach to greater diversity in clinical trials Read More »

Enabling new models of care: pursuing pharma’s partnership potential

There is a huge, ongoing shift in how health and wellness is approached in the UK, and the changes will have important implications for NHS-industry partnerships. Transformative change is coming to the NHS and is set to radically alter how the UK’s health service cares for people at a population level. The NHS Long Term …

Enabling new models of care: pursuing pharma’s partnership potential Read More »

‘No going back’ for clinical trials after COVID

Trial sites have adapted swiftly to the restrictions of COVID-19, and patients have seen many knock-on benefits as a result. The next step is ensuring the industry does not regress to old ways of working once the pandemic is over, say Karen McIntyre and Allyson Small. COVID-19 has changed everything for clinical trials – but …

‘No going back’ for clinical trials after COVID Read More »

How patient insights are changing trial solutions

Patients have been asking for patient-centric trial solutions for years – the industry just hasn’t been listening. That’s according to Medidata’s Anthony Costello, who was bringing patient feedback into product design long before COVID-19. He tells us what insights pharma has been missing out on and how they can be harnessed to build better solutions. …

How patient insights are changing trial solutions Read More »

True patient-focused research through decentralised and hybrid trials

How can pharma improve the patient-centricity of its trials during COVID-19 and beyond? Experts from across the sector give their thoughts on the key approaches and technologies that are driving patient engagement forward. With COVID-19 presenting new barriers to running and recruiting for clinical trials, making studies patient-centric is more important now than ever before. …

True patient-focused research through decentralised and hybrid trials Read More »

Boosting the impact of patient services

New research from Accenture has revealed that adoption of patient support services hasn’t improved since 2015 despite increasing pharma investment. The company’s Jennifer Spada tells us how companies can boost awareness of their programmes to improve patient outcomes. As part of its drive towards patient centricity, the pharma industry has increasingly been building patient support …

Boosting the impact of patient services Read More »

Finding agility in unprecedented times

Nicole Farmer, general manager, UK & Ireland at Sanofi Genzyme, tells us how the company aimed for agile adaptation during COVID-19, and how these lessons are driving patient centricity going forward. 2020 has been a watershed year for every company in the industry – and for Nicole Farmer, general manager for the UK & Ireland …

Finding agility in unprecedented times Read More »

Patient journeys in the era of COVID-19

OPEN Health’s Richard Jones and Sumira Riaz assess the pandemic’s implications for understanding patients’ experiences and how the pharma industry can support them It’s impossible not to view healthcare in 2020 through the lens of the current global pandemic and COVID-19 is certainly set to cast a long shadow over patient needs and engagement. Even …

Patient journeys in the era of COVID-19 Read More »

How pharma needs to change for the era of digital health

Experts from Healthware Group explore how companies can rebuild their approach to digital from the ground up for the benefit of patients. Digital is not just a nice-to-have for pharma companies – it’s a necessity for ensuring that patients have the best possible outcomes in modern healthcare systems. With digital tools and techniques being able …

How pharma needs to change for the era of digital health Read More »

Deep Dive: Patients and Partnerships

As this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – it requires companies to truly listen to, engage with and partner with the patients they serve, and in putting this month’s Deep Dive together it’s been great to see that so many pharma firms are now taking …

Deep Dive: Patients and Partnerships Read More »

VR, COVID and ensuring safety with cutting-edge tech

Not too long ago virtual reality (VR) tech might have seemed like a dream, but now it’s being harnessed by the healthcare industry for a wide variety of purposes, and during COVID-19 has helped educate physicians when real-world training isn’t feasible Commercial VR is still a relatively fresh prospect, but already the pharma and healthcare …

VR, COVID and ensuring safety with cutting-edge tech Read More »

Navigating the NHS as a digital start-up

We speak to finalists from the Greater Manchester Future of Health accelerator to find out how digital start-ups can overcome the challenges small companies face in bringing their technologies into the NHS. Right now the NHS is embracing digital to an extent no one could have foreseen a year ago – but that doesn’t mean …

Navigating the NHS as a digital start-up Read More »

A pivotal moment for digital health adoption

Former chief digital officer for the NHS, Juliet Bauer, is now applying her experience to the private sector through video consultation firm Livi. She shares her thoughts on how well the NHS is integrating digital health and what the public and private sectors can do to further boost adoption. Bauer’s path to working in the …

A pivotal moment for digital health adoption Read More »

What will the digital health ecosystem look like post-COVID?

COVID-19 has turned the world on its head and healthcare systems have had to respond rapidly to match the sudden changes created by lockdown. Digital health had already been building a presence before the pandemic, but the tools it offers have been essential to counter the disruption caused by the coronavirus, reports Richard Staines. COVID-19 …

What will the digital health ecosystem look like post-COVID? Read More »

3 innovations booming during COVID and how to adopt them successfully

Research Partnership’s Vicki Newlove explores research into digital change during COVID-19 to find out what business questions pharma needs to address to succeed with innovations. Pharma companies are facing a confusing and uncertain future, and no one can say how the industry might look in a year’s time, or what the balance of digital and …

3 innovations booming during COVID and how to adopt them successfully Read More »

Digital therapeutics: Why human psychology is key to adoption

The healthcare system is running at its limits in many countries worldwide. One reason is the growing demand for healthcare, largely driven by the rise of chronic diseases. COVID-19 has further underscored just how stretched the system is today. Is there any solution to the twin challenge of managing costs while extending capacity? We believe …

Digital therapeutics: Why human psychology is key to adoption Read More »

Building the infrastructure for successful digital health start-ups

2020 might go down as the year digital health truly began to boom – but to continue thriving, health tech start-ups will need a strong support network and an environment that fosters innovation. With advanced tech becoming ubiquitous, healthcare stakeholders finally embracing digital, and patients rapidly shifting their preferences, there has arguably never been a …

Building the infrastructure for successful digital health start-ups Read More »

Two decades of digital: the changing habits of pharma and HCPs

When Chris Cooper of EPG Health launched his ‘European Prescriber Guide’ software twenty years ago, he was among a select few taking digital in pharma seriously. Since then he has seen the industry slowly come to embrace every aspect of digital. He tells pharmaphorum how pharma can learn from the past to enter an innovative …

Two decades of digital: the changing habits of pharma and HCPs Read More »

Germany’s digital health changes will boost digital therapeutics in Europe

Digital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating market access challenge, say Olaf Schoeman and Emanuele Arcà. The last 12 months have shone a spotlight on digital transformation in Europe’s healthcare systems, with all the signs pointing to digital therapeutics (DTx) moving ever more into …

Germany’s digital health changes will boost digital therapeutics in Europe Read More »

A new dawn for clinical trial management

It’s time for pharma to take a 360-degree view of its clinical trial data and step into the future with near real-time trial management. The pharmaceutical industry faces an important inflection point in its approach to clinical trials and it’s one that COVID-19 has thrown into even sharper relief. The last great change for studies …

A new dawn for clinical trial management Read More »

The key elements driving the success of digital health

Ahead of Frontiers Health 2020, steering committee members Roberto Ascione and Paul Tunnah from Healthware give us their thoughts on the trends driving the bright future of digital health. It might be easy to think of pharma and healthcare as conservative industries, but the reality is that digital health is now far further along than …

The key elements driving the success of digital health Read More »

Deep Dive: Digital Health Innovation 2020

Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare industries. But this isn’t necessarily a bad thing – our interviewees also stressed that if companies can remain …

Deep Dive: Digital Health Innovation 2020 Read More »

Responding to dynamic shifts in value communications

OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies. Value in healthcare is a continually changing concept. As the needs of different stakeholders evolve and gain in prominence, pharmaceutical companies must be prepared to address value from various viewpoints using a variety of …

Responding to dynamic shifts in value communications Read More »

The tools and techniques making virtual patient simulations more realistic than ever

Patient simulations have been a key tool for educating physicians in some form for hundreds of years – and now cutting-edge technologies are helping them become more realistic and informative than ever. Medscape’s Martin Warters tells us more. Learning from a textbook can only take you so far, and when doctors need to put theory …

The tools and techniques making virtual patient simulations more realistic than ever Read More »

Cutting through the noise for HCPs

In a world producing more content than ever before, getting information to time-poor HCPs can be incredibly difficult – even if they want to find it. Ian Daley and Jonathan Macdonald from EPG Health tell us how pharma can take cues from digital publishing and companies like Amazon to make sure their messages get heard. …

Cutting through the noise for HCPs Read More »

GSK’s John Fleming on rethinking oncology from the ground up

What if we could look at cancer treatment from a completely fresh perspective? This is the philosophy GSK’s UK country medical head for oncology, John Fleming, wants to bring to the company as it rethinks its approach to cancer. Fleming joined Novartis in 2015, when GSK divested its oncology portfolio to the Swiss firm. It …

GSK’s John Fleming on rethinking oncology from the ground up Read More »

Commercialising innovative new medicines

As pharmaceutical ingenuity hits new heights, ensuring that patients gain access to innovative medicines requires a unique combination of evidence generation and communication Working with all stakeholders to generate evidence that communicates value, from early phase development to launch and reimbursement, is essential in therapy areas including oncology. These are challenging times for the pharmaceutical …

Commercialising innovative new medicines Read More »

How to increase haematologists’ and oncologists’ confidence with new treatments

A new whitepaper from Medscape highlights the difficulties haematologists and oncologists face in keeping up with rapid developments in treatment. We speak to the company’s Katie Lucero and Victoria Harvey-Jones to find out how independent medical education is changing to help HCPs increase their confidence in treating cancer patients. It’s an exciting time to be …

How to increase haematologists’ and oncologists’ confidence with new treatments Read More »

Clinical decision support tools will help oncologists manage complexity

Making treatment decisions is a tough choice for oncologists: a therapy might save or significantly extend one patient’s life but not deliver the desired outcome for another patient. Reaching this decision involves weighing a variety of data – from clinical trials to the patient’s medical background – and with the advent of more personalised oncology, …

Clinical decision support tools will help oncologists manage complexity Read More »